» Articles » PMID: 38932234

Development of Robust Freeze-Drying Process for Long-Term Stability of RVSV-SARS-CoV-2 Vaccine

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2024 Jun 27
PMID 38932234
Authors
Affiliations
Soon will be listed here.
Abstract

The thermostability of vaccines, particularly enveloped viral vectored vaccines, remains a challenge to their delivery wherever needed. The freeze-drying of viral vectored vaccines is a promising approach but remains challenging due to the water removal process from the outer and inner parts of the virus. In the case of enveloped viruses, freeze-drying induces increased stress on the envelope, which often leads to the inactivation of the virus. In this study, we designed a method to freeze-dry a recombinant vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike glycoprotein. Since the envelope of VSV is composed of 50% lipids and 50% protein, the formulation study focused on both the protein and lipid portions of the vector. Formulations were prepared primarily using sucrose, trehalose, and sorbitol as cryoprotectants; mannitol as a lyoprotectant; and histidine as a buffer. Initially, the infectivity of rVSV-SARS-CoV-2 and the cake stability were investigated at different final moisture content levels. High recovery of the infectious viral titer (~0.5 to 1 log loss) was found at 3-6% moisture content, with no deterioration in the freeze-dried cakes. To further minimize infectious viral titer loss, the composition and concentration of the excipients were studied. An increase from 5 to 10% in both the cryoprotectants and lyoprotectant, together with the addition of 0.5% gelatin, resulted in the improved recovery of the infectious virus titer and stable cake formation. Moreover, the secondary drying temperature of the freeze-drying process showed a significant impact on the infectivity of rVSV-SARS-CoV-2. The infectivity of the vector declined drastically when the temperature was raised above 20 °C. Throughout a long-term stability study, formulations containing 10% sugar (sucrose/trehalose), 10% mannitol, 0.5% gelatin, and 10 mM histidine showed satisfactory stability for six months at 2-8 °C. The development of this freeze-drying process and the optimized formulation minimize the need for a costly cold chain distribution system.

Citing Articles

Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach.

Khan M, Wagner C, Kamen A Vaccines (Basel). 2024; 12(11).

PMID: 39591143 PMC: 11598241. DOI: 10.3390/vaccines12111240.

References
1.
Kiesslich S, Kim G, Shen C, Kang C, Kamen A . Bioreactor production of rVSV-based vectors in Vero cell suspension cultures. Biotechnol Bioeng. 2021; 118(7):2649-2659. PMC: 8252067. DOI: 10.1002/bit.27785. View

2.
Kis Z . Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain. Pharmaceutics. 2022; 14(2). PMC: 8877932. DOI: 10.3390/pharmaceutics14020430. View

3.
Greiff D . Stabilities of suspensions of influenza virus dried by sublimation of ice in vacuo to different contents of residual moisture and sealed under different gases. Appl Microbiol. 1970; 20(6):935-8. PMC: 377086. DOI: 10.1128/am.20.6.935-938.1970. View

4.
Bogale H, Amhare A, Bogale A . Assessment of factors affecting vaccine cold chain management practice in public health institutions in east Gojam zone of Amhara region. BMC Public Health. 2019; 19(1):1433. PMC: 6824010. DOI: 10.1186/s12889-019-7786-x. View

5.
Hansen L, Daoussi R, Vervaet C, Remon J, De Beer T . Freeze-drying of live virus vaccines: A review. Vaccine. 2015; 33(42):5507-5519. DOI: 10.1016/j.vaccine.2015.08.085. View